NCT01084265View on ClinicalTrials.gov

A Study Using Recombinant Human Luteinizing Hormone (r-hLH, Luveris®) in the Treatment of Chinese Women With Hypogonadotropic Hypogonadism

PHASE3CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

December 31, 2005

Study Completion Date

December 31, 2005

Conditions
Hypogonadism
Interventions
DRUG

Recombinant human luteinizing hormone (r-hLH)

One r-hLH (75 International Units \[IU\]) injection s.c. once daily.

DRUG

Recombinant human follicle-stimulating hormone (r-hFSH)

One r-hFSH (150 IU) injection s.c. once daily.

DRUG

Human chorionic gonadotropin (hCG)

After adequate follicular response, ovulation induction was triggered by an injection of 10,000 IU hCG.

Trial Locations (1)

100730

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
collaborator

Merck Pte. Ltd., Singapore

INDUSTRY

lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT01084265 - A Study Using Recombinant Human Luteinizing Hormone (r-hLH, Luveris®) in the Treatment of Chinese Women With Hypogonadotropic Hypogonadism | Biotech Hunter | Biotech Hunter